Loading…
Loading…
Don't catch a falling knife.
Novo Nordisk was first to market with a GLP-1 weight-loss drug, but lost the lead to Eli Lilly. Novo Nordisk has been working hard to regain lost market share in the GLP-1 space.
NVO's semaglutide cuts BMI in children with obesity in phase III study, with 40.4% no longer classified as having obesity after 68 weeks.
Netflix, Uber, and Novo Nordisk are all excellent, undervalued stocks to buy today.
Lilly and J&J offer distinct paths for investors, with strong growth, expanding pipelines and key headwinds shaping their outlooks.
Novo Nordisk invented the GLP-1 category, told the world that weight loss was the least important thing its drugs did, and then watched a competitor take market share by promising a bigger number. Mike Doustdar became president and CEO of Novo Nordisk in August 2025, after 34 years at the company that began with a summer job making photocopies in its Vienna office.
Novo Nordisk said on Monday it had halted two additional trials of its experimental cardiovascular drug ziltivekimab, further denting the Danish drugmaker's efforts to diversify beyond its blockbuster obesity and diabetes franchise.
The Danish drugmaker said the clinical trial met its primary goal after 68 weeks of treatment.